Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY21.40 CNY
Change Today -0.83 / -3.73%
Volume 12.8M
As of 3:00 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

anhui anke biotechnology g-a (300009) Snapshot

Open
CNY21.20
Previous Close
CNY22.23
Day High
CNY23.50
Day Low
CNY20.01
52 Week High
06/12/15 - CNY42.78
52 Week Low
07/3/14 - CNY11.02
Market Cap
8.1B
Average Volume 10 Days
10.2M
EPS TTM
CNY0.29
Shares Outstanding
377.5M
EX-Date
04/17/15
P/E TM
73.4x
Dividend
CNY0.12
Dividend Yield
0.54%
Current Stock Chart for ANHUI ANKE BIOTECHNOLOGY G-A (300009)

Related News

No related news articles were found.

anhui anke biotechnology g-a (300009) Related Businessweek News

No Related Businessweek News Found

anhui anke biotechnology g-a (300009) Details

Anhui Anke Biotechnology (Group) Co., Ltd. develops, manufactures, and markets pharmaceuticals and health-care products in China and internationally. It offers recombinant human interferon alpha 2b for injection, interferon alpha 2b creams, interferon alpha 2b eye drops, and interferon alpha 2b suppository; and recombinant human growth hormone/somatropin for injection under the Ansomone name. The company also provides monoclonal antibody affinity gel to a-interferon; diagnostic kits; traditional Chinese medicines and synthetic drugs; and adefovir dipivoxil tablets, an anti-virus medicine for oral administration. Anhui Anke Biotechnology (Group) Co., Ltd. is based in Hefei, China.

anhui anke biotechnology g-a (300009) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

anhui anke biotechnology g-a (300009) Key Developments

Anhui Anke Biotechnology (Group) Co., Ltd. Signs on Cooperation Framework Agreement with Persongen Biomedicine

Anhui Anke Biotechnology (Group) Co., Ltd. signed a cooperation framework agreement with PersonGen Biomedicine on June 12, 2015 to cooperate in the cell immunotherapy in accordance with relevant laws and regulations. The two sides agreed to work together to set up a limited liability company to buy part of cells immunotherapy technologies, products and related technological achievements owned by PersonGen. The newborn specializes in the research and development, large-scale production and clinical application of CAR-T cells and the research and development, large-scale production and clinical application of NK cells and CTL cells. Registered in Suzhou, Jiangsu province, the new company's paid-in registered capital reaches CNY 100 million, in which Anke holds a 49% stake and PersonGen holds a 51% stake.

Anhui Anke Biotechnology (Group) Co., Ltd., Special/Extraordinary Shareholders Meeting, Jun 24, 2015

Anhui Anke Biotechnology (Group) Co., Ltd., Special/Extraordinary Shareholders Meeting, Jun 24, 2015., at 14:30 China Standard Time. Agenda: To consider the compliance with relevant laws and regulations of the assets purchase via share offering and cash payment and raising matching fund; to consider scheme for connected transaction regarding assets purchase via share offering and cash payment and raising matching fund; to sign conditional agreement on profit forecast compensation and supplementary agreement; to consider the transaction is in compliance with the 4th article in the Provisions on Several Issues Concerning the Regulation of Major Assets Restructuring by Listed Companies; to consider audit report, evaluation and profit forecast audit report related to the transaction; to consider the 2015 employee stock ownership plan; to sign conditional share subscription agreement with the person in charge of employee stock ownership plan; to consider the 2015 formulation of management rules on the first phase employee stock ownership plan.

Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q1, 2015 Results on Apr 23, 2015

Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q1, 2015 results on Apr 23, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
300009:CH CNY21.40 CNY -0.83

300009 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 300009.
View Industry Companies
 

Industry Analysis

300009

Industry Average

Valuation 300009 Industry Range
Price/Earnings 80.4x
Price/Sales 16.1x
Price/Book 12.9x
Price/Cash Flow 80.7x
TEV/Sales 15.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANHUI ANKE BIOTECHNOLOGY G-A, please visit www.ankebio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.